Actavis Laboratories FL, Inc. Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Actavis Laboratories FL, Inc. Pharmaceutical Import Records from India — 7 Products, $12.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Actavis Laboratories FL, Inc. — Pharmaceutical Importer Profile (2026) | 7 Products, $12.3M Trade | TransData Nexus

Actavis Laboratories FL, Inc.

Pharmaceutical Importer · United States · CNS & Psychiatric Focus · $12.3M Total Trade · DGFT Verified

Actavis Laboratories FL, Inc. is a pharmaceutical importer based in United States with a total trade value of $12.3M across 7 products in 5 therapeutic categories. Based on 360 verified import shipments from Indian Customs (DGFT) records, Actavis Laboratories FL, Inc. is the #1 buyer in 1 product including Alprazolam. Actavis Laboratories FL, Inc. sources from 1 verified Indian supplier, with Watson Pharma Private Limited accounting for 100.0% of imports.

Actavis Laboratories FL, Inc. — Import Portfolio & Supplier Network

Actavis Laboratories FL, Inc. import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Actavis Laboratories FL, Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Watson Pharma Private Limited	$24.6M	681	100.0%

Actavis Laboratories FL, Inc. sources from 1 verified Indian supplier across 233 distinct formulations. The sourcing is highly concentrated — Watson Pharma Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Labetalol hydrochloride tablets USP	$1.1M	21
Potassium citrate extended release	$1.0M	24
Labetalol hydrochloride tablets USP	$950.0K	19
Alprazolam tablets USP 1 MG (batch	$690.7K	19
Alprazolam tablets USP 2 MG (batch	$629.3K	16
Triamterene and hydrochlorothiazide	$600.0K	12
Alprazolam tablets USP 0.5 MG (batch no.	$565.3K	20
Glipizide tablets USP 5 MG (batch	$564.4K	20
Alprazolam tablets USP 0.25 MG (batch	$516.9K	20
Primidone tablets USP 250 MG (batch	$500.0K	10
Glipizide tablets USP 10 MG (batch no	$493.5K	18
Glipizide tablets USP 10 MG (batch	$435.6K	16
Glipizide tablets USP 10 MG (batch	$431.8K	16
Glipizide tablets USP 5 MG (batch no	$422.6K	15
Minocycline hydrochloride capsules, USP	$400.0K	8

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Alprazolam	CNS & Psychiatric	$7.5M	234	23.5%	1
2	Prednisone	Respiratory	$2.6M	52	7.4%	3
3	Verapamil	Cardiovascular	$700.0K	14	0.4%	16
4	Propranolol	Cardiovascular	$660.5K	36	1.1%	5
5	Minocycline	Advanced Antibiotics	$400.0K	8	1.8%	2
6	Lisinopril	Cardiovascular	$379.6K	13	0.6%	13
7	Colchicine	Lipid & Metabolism	$150.0K	3	0.7%	2

Actavis Laboratories FL, Inc. imports 7 pharmaceutical products across 5 categories into United States totaling $12.3M. The company is the #1 buyer for 1 product: Alprazolam.

Actavis Laboratories FL, Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Actavis Laboratories FL, Inc. is a pharmaceutical company based in Davie, Florida, specializing in the importation and distribution of finished pharmaceutical formulations. Established on November 21, 2002, the company operates as a subsidiary of Teva Pharmaceuticals, a global leader in generic and specialty medicines. Actavis Laboratories FL, Inc. plays a significant role in the United States pharmaceutical distribution network, focusing on sourcing and supplying a diverse range of generic medications to meet market demands.

2Distribution Network

The company's primary distribution center is located at 4955 Orange Drive, Davie, Florida 33314. This facility serves as the central hub for logistics and distribution operations, ensuring efficient delivery of pharmaceutical products across the United States. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Actavis Laboratories FL, Inc. is known for its robust distribution network, facilitating timely and reliable supply to various healthcare providers nationwide.

3Industry Role

Actavis Laboratories FL, Inc. functions as a pharmaceutical importer and distributor within the United States market. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of generic medications to meet the needs of healthcare providers and patients. This role is crucial in enhancing the accessibility and affordability of essential medicines across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Actavis Laboratories FL, Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Actavis Laboratories FL, Inc. demonstrates a high degree of supplier concentration, with a total import value of $12.3 million USD from India, comprising 360 shipments. All these imports are sourced from a single supplier, WATSON PHARMA PRIVATE LIMITED, indicating a strategic partnership or exclusive distribution agreement. This single-source dependency may present risks related to supply chain disruptions or changes in supplier dynamics. However, the consistent volume and frequency of shipments suggest a stable and reliable relationship between Actavis Laboratories FL, Inc. and WATSON PHARMA PRIVATE LIMITED.

2Supply Chain Resilience

The resilience of Actavis Laboratories FL, Inc.'s supply chain is closely tied to its exclusive sourcing arrangement with WATSON PHARMA PRIVATE LIMITED. The lack of backup suppliers and the concentration on a single supplier may expose the company to risks such as supply interruptions or geopolitical issues affecting trade routes. Additionally, the limited diversity in imported formulations could impact the company's ability to adapt to changing market demands or regulatory requirements. Ensuring the regulatory compliance of WATSON PHARMA PRIVATE LIMITED, including adherence to Good Manufacturing Practices (GMP), is essential to maintain the quality and reliability of the supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs, including generics, ensuring they meet the necessary standards before entering the U.S. market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Foreign manufacturers must register with the FDA and obtain an establishment registration number. Additionally, they must comply with the FDA's Good Manufacturing Practice (GMP) regulations, which are aligned with international standards such as EU GMP, WHO GMP, and PIC/S. These certifications ensure that manufacturing processes meet the required quality standards. Wholesale distributors like Actavis Laboratories FL, Inc. must also obtain appropriate state licenses to operate legally within the U.S.

3Quality & Labeling

Actavis Laboratories FL, Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Actavis Laboratories FL, Inc. focuses on importing pharmaceutical products in the Central Nervous System (CNS) & Psychiatric, Respiratory, and Cardiovascular therapeutic categories. This strategic focus aligns with market demand for treatments in these areas, addressing prevalent health conditions and contributing to the company's competitive positioning in the U.S. market. The high import value of Alprazolam, a CNS & Psychiatric medication, underscores the significant demand for such products.

2Sourcing Profile

Actavis Laboratories FL, Inc. employs a sourcing strategy that emphasizes high-volume imports of specific generic medications, particularly those with established efficacy and safety profiles. The company's preference for sourcing from India is likely due to the country's robust pharmaceutical manufacturing capabilities, cost-effectiveness, and adherence to international quality standards. This approach enables Actavis Laboratories FL, Inc. to offer a reliable supply of essential medications to the U.S. market.

3Market Positioning

Based on its product mix, Actavis Laboratories FL, Inc. serves the wholesale distribution segment of the United States pharmaceutical market. By importing and distributing generic medications, the company plays a crucial role in supplying healthcare providers, including retail pharmacies, hospitals, and clinics, with affordable and effective treatment options. This positioning supports the broader healthcare system by enhancing access to necessary medications.

Seller's Guide — How to Become a Supplier to Actavis Laboratories FL, Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Actavis Laboratories FL, Inc. by offering high-quality generic medications that meet FDA standards. Gaps in Actavis Laboratories FL, Inc.'s current sourcing include a limited supplier base and a narrow range of imported formulations. Indian exporters can capitalize on these gaps by providing diverse product offerings, competitive pricing, and ensuring compliance with regulatory requirements to become viable alternative suppliers.

2Requirements & Qualifications

Indian exporters aiming to supply Actavis Laboratories FL, Inc. and the U.S. market must obtain FDA registration and comply with GMP standards recognized by the FDA. Additionally, they must ensure that their products meet FDA labeling requirements and pass necessary quality control tests. Maintaining certifications such as EU GMP, WHO GMP, or PIC/S can enhance credibility and facilitate the approval process.

3How to Approach

Frequently Asked Questions — Actavis Laboratories FL, Inc.

What products does Actavis Laboratories FL, Inc. import from India?

Actavis Laboratories FL, Inc. imports 7 pharmaceutical products across 5 categories. Top imports: Alprazolam ($7.5M), Prednisone ($2.6M), Verapamil ($700.0K), Propranolol ($660.5K), Minocycline ($400.0K).

Who supplies pharmaceuticals to Actavis Laboratories FL, Inc. from India?

Actavis Laboratories FL, Inc. sources from 1 verified Indian suppliers. The primary supplier is Watson Pharma Private Limited (100.0% of imports, $24.6M).

What is Actavis Laboratories FL, Inc.'s total pharmaceutical import value?

Actavis Laboratories FL, Inc.'s total pharmaceutical import value from India is $12.3M, based on 360 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Actavis Laboratories FL, Inc. focus on?

Actavis Laboratories FL, Inc. imports across 5 categories. The largest: CNS & Psychiatric (60.4%), Respiratory (21.1%), Cardiovascular (14.1%).

Get Full Actavis Laboratories FL, Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.